AUSTRALIAN CLINICAL LABS LIMITED (ACL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ACL

ACL - AUSTRALIAN CLINICAL LABS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.46
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.71

27 Aug
2025

0.040

OPEN

$2.70

1.50%

HIGH

$2.74

1,952,030

LOW

$2.63

TARGET
$3.20 18.1% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
AHX . ALC . BMT . DOC . EBO . HLS . IDX . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
ACL: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 17.2 18.6 xxx
DPS (cps) xxx 12.5 12.5 xxx
EPS Growth xxx 42.6% 8.5% xxx
DPS Growth xxx 4.2% - 0.4% xxx
PE Ratio xxx N/A 15.1 xxx
Dividend Yield xxx N/A 4.4% xxx
Div Pay Ratio(%) xxx 72.9% 66.9% xxx

Dividend yield today if purchased 3 years ago: 2.99%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 4.46

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 28/03 - ex-div 3c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx17.2
DPS All xxxxxxxxxxxxxxx12.5
Sales/Revenue xxxxxxxxxxxxxxx736.1 M
Book Value Per Share xxxxxxxxxxxxxxx88.1
Net Operating Cash Flow xxxxxxxxxxxxxxx182.8 M
Net Profit Margin xxxxxxxxxxxxxxx4.41 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx18.59 %
Return on Invested Capital xxxxxxxxxxxxxxx8.83 %
Return on Assets xxxxxxxxxxxxxxx5.55 %
Return on Equity xxxxxxxxxxxxxxx18.59 %
Return on Total Capital xxxxxxxxxxxxxxx13.25 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx149.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx109 M
Long Term Debt xxxxxxxxxxxxxxx182 M
Total Debt xxxxxxxxxxxxxxx290 M
Goodwill - Gross xxxxxxxxxxxxxxx159 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx22 M
Price To Book Value xxxxxxxxxxxxxxx3.15

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx8.4 M
Capex % of Sales xxxxxxxxxxxxxxx1.14 %
Cost of Goods Sold xxxxxxxxxxxxxxx583 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx90 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

27/08/2025

1

Buy

$3.50

29.15%

Ord Minnett observes an in-line FY25 earnings (EBIT) result for Australian Clinical Labs, up 9% on the prior year to $68m. Revenue growth came in above the broader market, and managed costs facilitated a 2H25 earnings (EBIT) margin of 10.9%.

FY26 guidance was better than the analyst feared, with revenue of $760m–$780m, up 3%–5%, and earnings (EBIT) of $67m–$73m.

Management flagged at least $8m in incremental earnings (EBIT) in FY27 due to upfront episode billing, price rises on non-MBS tests, and improved labour and operating efficiency.

No change to Buy rating. Target retained at $3.50.

FORECAST
Ord Minnett forecasts a full year FY26 dividend of 11.90 cents and EPS of 17.90 cents.
Ord Minnett forecasts a full year FY27 dividend of 14.00 cents and EPS of 21.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

ACL STOCK CHART

FNArena News on ACL

1
FNArena Corporate Results Monitor – 27-08-2025

Aug 27 2025 - Australia
2
Rudi’s View: Navigating Covid Legacies

Jul 16 2025 - Rudi's View
3
Australian Broker Call *Extra* Edition – Apr 14, 2025

Apr 14 2025 - Daily Market Reports
4
In Brief: Tariffs, Healthcare & Wealth Platforms

Apr 11 2025 - Weekly Reports
5
Rudi’s View: To Sell Or Not To Sell

Mar 06 2025 - Rudi's View

Latest Healthcare services News

1
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
2
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
5
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
6
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
7
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
8
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
9
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
10
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps